These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23440406)

  • 41. Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density.
    Hamed EA; Mohamed NA; El-Metwally TH; Kamal MM
    J Pediatr Hematol Oncol; 2010 May; 32(4):267-73. PubMed ID: 20445416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?
    Wagner D; Fahrleitner-Pammer A
    Wien Med Wochenschr; 2010 Sep; 160(17-18):452-7. PubMed ID: 20714810
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
    Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
    J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
    Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
    Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
    Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The RANKL-OPG system in clinical periodontology.
    Belibasakis GN; Bostanci N
    J Clin Periodontol; 2012 Mar; 39(3):239-48. PubMed ID: 22092994
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum levels of the osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, metalloproteinase-1 (MMP-1) and tissue inhibitors of MMP-1 levels are increased in men 6 months after acute myocardial infarction.
    Halapas A; Zacharoulis A; Theocharis S; Karavidas A; Korres D; Papadopoulos K; Katopodis H; Stavropoulou A; Lembessis P; Xiromeritis C; Zacharoulis A; Koutsilieris M
    Clin Chem Lab Med; 2008; 46(4):510-6. PubMed ID: 18298349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
    J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Osteoprotegerin and nuclear factor-kappaB ligand are associated with leptin and adiponectin levels, in apparently healthy women.
    Tenta R; Panagiotakos DB; Fragopoulou E; Nomikos T; Pitsavos C; Chrysohoou C; Antonopoulou S; Stefanadis C
    J Musculoskelet Neuronal Interact; 2010 Jun; 10(2):174-9. PubMed ID: 20516635
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Accelerated cartilage resorption by chondroclasts during bone fracture healing in osteoprotegerin-deficient mice.
    Ota N; Takaishi H; Kosaki N; Takito J; Yoda M; Tohmonda T; Kimura T; Okada Y; Yasuda H; Kawaguchi H; Matsumoto M; Chiba K; Ikegami H; Toyama Y
    Endocrinology; 2009 Nov; 150(11):4823-34. PubMed ID: 19819969
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing.
    Colombini A; Lombardi G; Galliera E; Dogliotti G; Randelli P; Meerssemann A; Mineo G; Cabitza P; Corsi MM
    Int Orthop; 2011 May; 35(5):777-82. PubMed ID: 20623281
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum levels of RANKL and OPG, and the RANKL/OPG ratio in bisphosphonate-related osteonecrosis of the jaw: Are they useful biomarkers for the advanced stages of osteonecrosis?
    Bagan L; Jiménez Y; Leopoldo M; Rubert A; Bagan J
    Med Oral Patol Oral Cir Bucal; 2017 Sep; 22(5):e542-e547. PubMed ID: 28809381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Organic Gallium Treatment Improves Osteoporotic Fracture Healing Through Affecting the OPG/RANKL Ratio and Expression of Serum Inflammatory Cytokines in Ovariectomized Rats.
    Wang J; He M; Wang G; Fu Q
    Biol Trace Elem Res; 2018 Jun; 183(2):270-279. PubMed ID: 28836172
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of OPG-RANKL ratio with left ventricular hypertrophy and geometric remodeling in male overweight/obese youths.
    Zampetti S; Lucantoni F; Pacifico L; Campagna G; Versacci P; Pierimarchi P; Buzzetti R
    J Endocrinol Invest; 2019 Apr; 42(4):427-434. PubMed ID: 30132289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.
    Widschwendter M; Burnell M; Fraser L; Rosenthal AN; Philpott S; Reisel D; Dubeau L; Cline M; Pan Y; Yi PC; Gareth Evans D; Jacobs IJ; Menon U; Wood CE; Dougall WC
    EBioMedicine; 2015 Oct; 2(10):1331-9. PubMed ID: 26629528
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of icariin on bone destruction and serum RANKL/OPG levels in type II collagen-induced arthritis rats].
    Liu YJ; Feng W; He DY; Wang QQ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Sep; 33(9):1221-5. PubMed ID: 24273978
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Osteoblast-specific overexpression of complement receptor C5aR1 impairs fracture healing.
    Bergdolt S; Kovtun A; Hägele Y; Liedert A; Schinke T; Amling M; Huber-Lang M; Ignatius A
    PLoS One; 2017; 12(6):e0179512. PubMed ID: 28614388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Status of the osteoclast-activating system in cosmonauts after long-duration missions to the International Space Station].
    Morukov IB; Rykova MP; Antropova EN; Berendeeva TA; Ponomarev SA; Morukov BV
    Aviakosm Ekolog Med; 2014; 48(6):10-5. PubMed ID: 25928978
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elevated serum osteoprotegerin is associated with decreased osteoclastic differentiation in stenotic aortic valves.
    Lis GJ; Czubek U; Jasinska M; Jasek E; Loboda A; Dulak J; Nessler J; Sadowski J; Litwin JA
    J Physiol Pharmacol; 2014 Jun; 65(3):377-82. PubMed ID: 24930509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study.
    Kelesidis T; Kendall MA; Yang OO; Hodis H; Currier JS
    AIDS Res Hum Retroviruses; 2013 Jun; 29(6):938-48. PubMed ID: 23351153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.